Kymera Therapeutics, Inc. (KYMR) Institutional Ownership

Ownership Summary

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has 249 institutional investors with active 13F positions as of December 2025.

• Collectively, these holders controlled 95.6% of Kymera Therapeutics's outstanding shares in December 2025, up from 93.5% in September 2025.
• Their total shares held in KYMR increased 10.27% from the prior quarter, while the number of investors in Kymera Therapeutics increased 39.11% year over year.
• Of these 249 holders, 157 added to their stakes in Kymera Therapeutics, 67 trimmed positions, and 25 made no changes.
• Combined, these investors held 83.47Mn shares in KYMR for December 2025, up by 7.77Mn shares quarter on quarter, and up 11.46Mn shares year over year.
• FMR LLC is the top holder of Kymera Therapeutics as of December 31, 2025, with 11.7Mn shares representing 13.4% of outstanding stock.
• The largest buyers of Kymera Therapeutics for the quarter ending December 2025 were PRICE T ROWE ASSOCIATES INC /MD/ (6.06Mn), T. Rowe Price Investment Management, Inc. (4.74Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.88Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (2.87Mn), FMR LLC (2.77Mn).
• The largest sales of KYMR for the quarter ending December 2025 came from Avoro Capital Advisors LLC (7.47Mn), Goldman Sachs Group Inc (592.2K), WELLINGTON MANAGEMENT GROUP LLP (523.25K), Federated Hermes, Inc. (227.24K), Squarepoint Ops LLC (146.59K).
• Business Quant data shows the 10 biggest positions in Kymera Therapeutics as of December 2025 are held by FMR LLC (11.7Mn), BAKER BROS. ADVISORS LP (8.66Mn), Avoro Capital Advisors LLC (7.47Mn), PRICE T ROWE ASSOCIATES INC /MD/ (6.06Mn), BVF INC/IL (5.5Mn), T. Rowe Price Investment Management, Inc. (5.46Mn), BlackRock, Inc. (5.06Mn), Atlas Venture Life Science Advisors, LLC (4.58Mn), WELLINGTON MANAGEMENT GROUP LLP (3.89Mn), Siren, L.L.C. (3.19Mn).